Covid-19 treatment update: follow the scientific evidence.
Identifieur interne : 001871 ( Main/Curation ); précédent : 001870; suivant : 001872Covid-19 treatment update: follow the scientific evidence.
Auteurs : Richard C. Becker [États-Unis]Source :
- Journal of thrombosis and thrombolysis [ 1573-742X ] ; 2020.
Descripteurs français
- KwdFr :
- Accessibilité des services de santé (MeSH), Animaux (MeSH), Antiviraux (effets indésirables), Antiviraux (ressources et distribution), Antiviraux (usage thérapeutique), Appréciation des risques (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (pathogénicité), Cardiotoxicité (MeSH), Essais cliniques comme sujet (MeSH), Facteurs de risque (MeSH), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (ressources et distribution), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (diagnostic), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Maladies cardiovasculaires (induit chimiquement), Médecine factuelle (MeSH), Pandémies (MeSH), Plan de recherche (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Résultat thérapeutique (MeSH), Sécurité des patients (MeSH).
- MESH :
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- effets indésirables : Antiviraux, Hydroxychloroquine.
- induit chimiquement : Maladies cardiovasculaires.
- pathogénicité : Betacoronavirus.
- ressources et distribution : Antiviraux, Hydroxychloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Hydroxychloroquine.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Accessibilité des services de santé, Animaux, Appréciation des risques, Cardiotoxicité, Essais cliniques comme sujet, Facteurs de risque, Humains, Médecine factuelle, Pandémies, Plan de recherche, Résultat thérapeutique, Sécurité des patients.
English descriptors
- KwdEn :
- Animals (MeSH), Antiviral Agents (adverse effects), Antiviral Agents (supply & distribution), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (pathogenicity), COVID-19 (MeSH), Cardiotoxicity (MeSH), Cardiovascular Diseases (chemically induced), Clinical Trials as Topic (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Evidence-Based Medicine (MeSH), Health Services Accessibility (MeSH), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (supply & distribution), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Patient Safety (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), Research Design (MeSH), Risk Assessment (MeSH), Risk Factors (MeSH), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Hydroxychloroquine.
- chemical , supply & distribution : Antiviral Agents, Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine.
- chemically induced : Cardiovascular Diseases.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Animals, COVID-19, Cardiotoxicity, Clinical Trials as Topic, Evidence-Based Medicine, Health Services Accessibility, Humans, Pandemics, Patient Safety, Research Design, Risk Assessment, Risk Factors, SARS-CoV-2, Treatment Outcome.
DOI: 10.1007/s11239-020-02120-9
PubMed: 32338320
PubMed Central: PMC7183928
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001871
Links to Exploration step
pubmed:32338320Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Covid-19 treatment update: follow the scientific evidence.</title><author><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name><affiliation wicri:level="1"><nlm:affiliation>Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, USA. richard.becker@uc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32338320</idno><idno type="pmid">32338320</idno><idno type="doi">10.1007/s11239-020-02120-9</idno><idno type="pmc">PMC7183928</idno><idno type="wicri:Area/Main/Corpus">001871</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001871</idno><idno type="wicri:Area/Main/Curation">001871</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001871</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Covid-19 treatment update: follow the scientific evidence.</title><author><name sortKey="Becker, Richard C" sort="Becker, Richard C" uniqKey="Becker R" first="Richard C" last="Becker">Richard C. Becker</name><affiliation wicri:level="1"><nlm:affiliation>Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, USA. richard.becker@uc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of thrombosis and thrombolysis</title><idno type="eISSN">1573-742X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (supply & distribution)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (pathogenicity)</term><term>COVID-19 (MeSH)</term><term>Cardiotoxicity (MeSH)</term><term>Cardiovascular Diseases (chemically induced)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Evidence-Based Medicine (MeSH)</term><term>Health Services Accessibility (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (supply & distribution)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Patient Safety (MeSH)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (virology)</term><term>Research Design (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Risk Factors (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accessibilité des services de santé (MeSH)</term><term>Animaux (MeSH)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (ressources et distribution)</term><term>Antiviraux (usage thérapeutique)</term><term>Appréciation des risques (MeSH)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (pathogénicité)</term><term>Cardiotoxicité (MeSH)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Hydroxychloroquine (ressources et distribution)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Maladies cardiovasculaires (induit chimiquement)</term><term>Médecine factuelle (MeSH)</term><term>Pandémies (MeSH)</term><term>Plan de recherche (MeSH)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term><term>Résultat thérapeutique (MeSH)</term><term>Sécurité des patients (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>COVID-19</term><term>Cardiotoxicity</term><term>Clinical Trials as Topic</term><term>Evidence-Based Medicine</term><term>Health Services Accessibility</term><term>Humans</term><term>Pandemics</term><term>Patient Safety</term><term>Research Design</term><term>Risk Assessment</term><term>Risk Factors</term><term>SARS-CoV-2</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Accessibilité des services de santé</term><term>Animaux</term><term>Appréciation des risques</term><term>Cardiotoxicité</term><term>Essais cliniques comme sujet</term><term>Facteurs de risque</term><term>Humains</term><term>Médecine factuelle</term><term>Pandémies</term><term>Plan de recherche</term><term>Résultat thérapeutique</term><term>Sécurité des patients</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32338320</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-742X</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of thrombosis and thrombolysis</Title><ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation></Journal><ArticleTitle>Covid-19 treatment update: follow the scientific evidence.</ArticleTitle><Pagination><MedlinePgn>43-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-020-02120-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Heart, Lung and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, USA. richard.becker@uc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Thromb Thrombolysis</MedlineTA><NlmUniqueID>9502018</NlmUniqueID><ISSNLinking>0929-5305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32338320</ArticleId><ArticleId IdType="doi">10.1007/s11239-020-02120-9</ArticleId><ArticleId IdType="pii">10.1007/s11239-020-02120-9</ArticleId><ArticleId IdType="pmc">PMC7183928</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morens DM, Daszak P, Taubenberger JK (2020) Escaping Pandora's box— another novel Coronavirus. N Eng J Med 382:1293–1295</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2002106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for disease control and prevention. JAMA.</Citation></Reference><Reference><Citation>Kupferschmidt K, Cohen J (2020) Race to find COVID-19 treatments accelerates. Science (New York, NY) 367:1412–1413</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.367.6485.1412</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakhar D, Kaur I (2020) Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med</Citation></Reference><Reference><Citation>Plowe CV (2005) Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol 295:55–79</Citation></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis 3:722–727</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(03)00806-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Boone BA, Murthy P, Miller-Ocuin J, Doerfler WR, Ellis JT, Liang X, Ross MA, Wallace CT, Sperry JL, Lotze MT, Neal MD, Zeh HJ 3rd (2018) Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC cancer 18:678</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-018-4584-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Tsuji-Hosokawa A, Willson C, Watanabe M, Si R, Lai N, Wang Z, Yuan JX, Wang J, Makino A (2020) Chloroquine differentially modulates coronary vasodilation in control and diabetic mice. Br J Pharmacol 177:314–327</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14864</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Xiao YC, Zhang GP, Hou N, Wu XQ, Chen WL, Luo JD, Zhang GS (2016) Chloroquine improves left ventricle diastolic function in streptozotocin-induced diabetic mice. Drug Des Dev Ther 10:2729–2737</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S111253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42:145–153</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-010-8243-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Blignaut M, Espach Y, van Vuuren M, Dhanabalan K, Huisamen B (2019) Revisiting the cardiotoxic effect of chloroquine. Cardiovasc Drugs Ther 33:1–11</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-018-06847-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323:264–268</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.08.085</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P (2009) Antiviral activity of chloroquine against human Coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53:3416–3421</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01509-08</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M, Tang T, Pang P, Li M, Ma R, Lu J, Shu J, You Y, Chen B, Liang J, Hong Z, Chen H, Kong L, Qin D, Pei D, Xia J, Jiang S and Shan H (2020) Treating COVID-19 with chloroquine. J Mol Cell Biol.</Citation></Reference><Reference><Citation>Al-Bari MA (2015) Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70:1608–1621</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkv018</ArticleId></ArticleIdList></Reference><Reference><Citation>Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38:653–671</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-018-0656-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohkuma S, Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327–3331</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.75.7.3327</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L (1993) Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 20:803–808</Citation></Reference><Reference><Citation>Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ (2000) Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 95:3460–3466</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V95.11.3460</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantini J, Scala CD, Chahinian H and Yahi N (2020) Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents 105960.</Citation></Reference><Reference><Citation>Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213–1218</Citation></Reference><Reference><Citation>Ali M, Girgis S, Hassan A, Rudick S, Becker RC (2018) Inflammation and coronary artery disease: from pathophysiology to Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Coron Artery Dis 29:429–437</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCA.0000000000000625</ArticleId></ArticleIdList></Reference><Reference><Citation>Newby AC (2015) Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation. Matrix Biol 44–46:157–166</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2015.01.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89:322–326</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(90)90345-E</ArticleId></ArticleIdList></Reference><Reference><Citation>Achuthan S, Ahluwalia J, Shafiq N, Bhalla A, Pareek A, Chandurkar N, Malhotra S (2015) Hydroxychloroquine's efficacy as an antiplatelet agent study in healthy volunteers: a proof of concept study. J Cardiovasc Pharmacol Ther 20:174–180</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248414546324</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, Lou W, Fortin PR (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41:919–931</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-018-0689-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W and Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis.</Citation></Reference><Reference><Citation>Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0156-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P and Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949.</Citation></Reference><Reference><Citation>Woosley RL, Black K, Heise CW, Romero K (2018) CredibleMeds.org: What does it offer? Trends Cardiovasc Med 28:94–99</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2017.07.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunker A, Kolanczyk DM, Maendel CM, Patel AR, Pettit NN (2016) Impact of the FDA Warning for Azithromycin and Risk for QT Prolongation on Utilization at an Academic Medical Center. Hosp Pharmacy 51:830–833</Citation><ArticleIdList><ArticleId IdType="doi">10.1310/hpj5110-830</ArticleId></ArticleIdList></Reference><Reference><Citation>Thind M, Rodriguez I, Kosari S, Turner JR (2020) How to prescribe drugs with an identified proarrhythmic liability. J Clin Pharmacol 60:284–294</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1551</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V (2017) Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm 39:424–432</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-017-0446-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba M, Val FdA, Sampaio VS, Alexandre MA, Melo GC, Brito M, Mourao M, Brito Sousa JD, Baia-da-Silva d, Guerra MVF, Hajjar L, Pinto RC, Balieiro A, Naveca FG, Xavier M, Salomao A, Siqueira A, Schwarzbolt A, Croda JHR, Nogueira ML, Romero G, Bassat Q, Fontes CJ, Albuquerque B, Daniel-Ribeiro C, Monteiro W and Lacerda M (2020) Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv. 2020.04.07.20056424.</Citation></Reference><Reference><Citation>Kieny MP, Salama P (2017) WHO R&D Blueprint: a global coordination mechanism for R&D preparedness. Lancet 389:2469–2470</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31635-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodcock J, LaVange LM (2017) Master protocols to study multiple therapies, multiple diseases, or both. N Eng J Med 377:62–70</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1510062</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001871 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001871 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32338320
|texte= Covid-19 treatment update: follow the scientific evidence.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32338320" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |